newborn

New publications in health economics and genomics 26th November 2024

James Buchanan Weekly new publication alerts , , , , , , , , ,

Seven publications over the past week:

  • Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study | link
  • Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews | link
  • Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework | link
  • Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies | link
  • Implementation of a National Prenatal Exome Sequencing Service in England: Cost-Effectiveness Analysis | link
  • Next-generation sequencing in oncology: challenges in economic evaluations | link
  • Cost-Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

What are the real costs of sequencing?

James Buchanan Paper review , , , , , , , , , , , , ,

I normally steer well clear of the topic of sequencing in newborn babies because this area raises so many social, legal and ethical questions that go way beyond the clinical/economics perspective that we’re used to considering. However, I read an interesting commentary piece the other day by Jacques Beckmann titled ‘Can we afford to sequence every newborn baby’s genome?’ which I think deserves a wider audience for two reasons. One, it reminded me of a comment that Professor Sir John Burn (director, NHS England) made during the recent Astellas Innovation Debate in London. Jonathan Dimbleby asked if he could see whole genome sequencing (WGS) being rolled out to everyone across the UK, to which he replied: “the reality is that even when we get the 100,000 Genomes Project fully operational and get it absorbed, we’ll only be doing maybe 30,000-50,000 whole genomes a year – we’d have to do 600,000 a year to catch up with the new babies”. Second, I think there are some points raised in this article that go beyond newborn screening and are directly applicable to the economic evaluation of genomic testing in a variety of clinical contexts.

Continue reading →